SymPAtHY
Financiado
A neurosplenic pathway coupling Immunity and Hypertension
Hypertension (HTN) is a leading cause of morbidity and mortality worldwide. During past decades, several therapies have been developed to afford an optimal blood pressure (BP) regulation. However, the prevalence of uncontrolled HT...
Hypertension (HTN) is a leading cause of morbidity and mortality worldwide. During past decades, several therapies have been developed to afford an optimal blood pressure (BP) regulation. However, the prevalence of uncontrolled HTN continues to rise, with a number of patients still resistant to all ongoing antihypertensive treatments, raising unsolved mechanistic challenges. In the last years, the most attractive novelty in HTN postulated that immune system has a crucial role in BP raising, as well as in end-organ damage. Several advances have been done in this field, but clear mechanistic explanations of how the immune system gets activated under hypertensive challenges is still unknown. It is becoming increasingly clear that, even in the regulation of body hemodynamic, the immune system and the autonomic nervous system serve as two major sensory organs capable to be activated upon manifold hits that perturb homeostasis. SymPAtHY is a multidisciplinary strategy aimed at discovering how nervous and immune systems couple in HTN. The concept of this project is to dissect the neuro-immune pathway responsible for BP rising and end-organ damage. The articulation in 3 MAIN AIMS will allow to afford the mechanistic insights from different perspectives. The overall objectives are as follows: 1) Central nervous system relay station coupling immunity and hypertension. 2) Splenic immune mechanisms: from sympathetic drive to T cell egress; 3) T cells in target organs: from the spleen to vessels and kidney. The results of this strategy will unravel important new mechanistic insights in HTN and particularly will have significant implications for understanding how immunity and autonomic nervous system cooperate to rise BP. Based on the emerging view of HTN as an immune disorder, we believe that this strategy will add decisive knowledge in this field that could pave the way for developing immunotherapies for the treatment of resistant HTN.
ver más
Duración del proyecto: 60 meses
Fecha Inicio: 2017-11-21
Fecha Fin: 2022-11-30
Fecha Fin: 2022-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-11-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2017-STG:
ERC Starting Grant
Cerrada
hace 8 años
Presupuesto
El presupuesto total del proyecto asciende a
1M€
Líder del proyecto
UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
759.26K€ |
Participante